SIOC 中文
CJOG
Adv search

Chinese Journal of Organic Chemistry >

2020 , Vol. 40 >Issue 6: 1409 - 1422

DOI: https://doi.org/10.6023/cjoc202003015

ACCOUNT

Efficient Synthesis of Chiral Drugs Facilated by P-Chiral Phosphorus Ligands

  • Xu Ronghua ,
  • Yang He ,
  • Tang Wenjun
Expand
  • a School of Physical Science and Technology, ShanghaiTech University, Shanghai 201210;
    b State Key Laboratory of Bio-Organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Science, Shanghai 200032;
    c Shenzhen Grubbs Institute, Southern University of Science and Technology, Shenzhen, Guangdong 518055;
    d School of Chemistry and Material Sciences, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024

Received date: 2020-03-06

  Revised date: 2020-04-06

  Online published: 2020-04-17

Supported by

Project supported by the National Natural Science Foundation of China (Nos. 21725205, 21432007, 21572246), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB20000000) and the K. C. Wong Education Foundation.

Fold

Abstract

Development of efficient and practical asymmetric catalytic reactions plays a pivotal role for the concise syntheses of chiral drugs. Chiral ligands and catalysts are crucial for the selectivity and reactivity of the catalytic reactions. In this account, the design and development of a series of P-chiral mono- and bis-phosphorus ligands were summarized based on a benzooxaphosphane backbone and their applications in the synthesis of chiral drugs. Beside their P-chirality, these ligands are structurally rigid, sterically bulky, and electron-rich, providing good physical properties and tunabilities. Facilitated by these chiral ligands, a series of efficient and practical reactions including asymmetric hydrogenation, asymmetric cross-coupling, asymmetric cyclization, and asymmetric nucleophilic additions have been developed. The excellent conversions, yields, regioselectivities, enantioselectivities, and broad substrate scope have enabled concise and efficient syntheses of a series of chiral drugs.

Key words： chiral phosphorus ligands; transition metal catalysis; asymmetric synthesis; enantioselectivity; chiral drugs

Cite this article

Xu Ronghua , Yang He , Tang Wenjun . Efficient Synthesis of Chiral Drugs Facilated by P-Chiral Phosphorus Ligands[J]. Chinese Journal of Organic Chemistry, 2020 , 40(6) : 1409 -1422 . DOI: 10.6023/cjoc202003015

References

[1] Lin, G. Q.; Wang, M. X. Chiral Synthesis and Chiral Drugs, Chemical Industry Press, Beijing, 2008, pp. 1~4(in Chinese). (林国强, 王梅祥, 手性合成和手性药物, 化学工业出版社, 北京, 2008, pp. 1~4.)
[2] Lin, G. Q.; Sun, X. W.; Chen, Y. Q.; Li, Y. M.; Chen, X. Z. Chiral Synthesis-Asymmetric Reactions and Their Applications, Science Press, Beijing, 2013, pp. 36~38(in Chinese). (林国强, 孙兴文, 陈耀全, 李月明, 陈新滋, 手性合成——不对称反应及其应用, 科学出版社, 北京, 2013, pp. 36~38.)
[3] Tang, W; Zhang, X. Chem. Rev. 2003, 103, 3029.
[4] Tang, W. In Proceedings of the 11th National Conference on Natural Organic Chemistry of the Chinese Chemical Society, Volume 1, Shanghai, 2019, p. 71(in Chinese). (汤文军, 中国化学会第十一届全国天然有机化学学术会议论文集, 第一册, 上海, 2019, p. 71.)
[5] (a) Xu, G.; Senanayake, C. H; Tang, W. Acc. Chem. Res. 2019, 52, 1601.
(b) Wu, T.; Xu, G.; Tang, W. Aldrichim. Acta 2020, 53, 27.
(c) Tang, W.; Li, K. Strem Chem. 2019, XXXI, 1.
[6] Liu, G.; Liu, X.; Cai, Z.; Jiao, G.; Xu, G.; Tang, W. Angew. Chem., Int. Ed. 2013, 52, 42359.
[7] Li, C.; Wan, F; Chen, Y.; Peng, H.; Tang, W.; Yu, S.; McWilliams, H. C.; Mustakis, J.; Samp, L.; Maguire, R. J. Angew. Chem., Int. Ed. 2019, 58, 13573.
[8] Daniella M. S.; Yuka K.; Alejandro V.; Michael W.; Massimo G.; John J. O. Nat. Rev. Drug Discovery 2017, 16, 843.
[9] Patil, Y. S.; Bonde, N. L.; Kekan, A. S.; Sathe, D. G.; Das, A. Org. Process Res. Dev. 2014, 18, 1714.
[10] Zhu, J.; Huang, L.; Dong, W.; Li, N.; Yu, X.; Deng, W.; Tang, W. Angew. Chem., Int. Ed. 2019, 58, 16119.
[11] Rottmann, M.; McNamara, C.; Yeung, B. K. S. Science 2010, 329, 1175.
[12] Huang, L.; Zhu, J.; Jiao, G.; Wang, Z.; Yu, X.; Deng, W.; Tang W. Angew. Chem., Int. Ed. 2016, 55, 4527.
[13] Dhillon, S.; Scott, L. J.; Plosker, G. L. CNS Drugs 2006, 20, 763.
[14] Yang, H.; Tang, W. Chem. Rec. 2020, 20, 23.
[15] Cao, Z.; Du, K.; Liu, J. H.; Tang, W. Tetrahedron 2016, 72, 1782.
[16] Li, B.; Li, T.; Aliyu, M. A.; Li, Z.; Tang, W. Angew. Chem., Int. Ed. 2019, 58, 11355.
[17] Dodou, K.; Anderson, R. J.; Lough, W. J.; Small, D. A. P.; Shelley, M. D.; Groundwater, P. W. Bioorg. Med. Chem. 2005, 13, 4228.
[18] (a) Xu, G.; Fu, W.; Liu, G.; Senanayake, C. H.; Tang, W. J. Am. Chem. Soc. 2014, 136, 570.
(b) Xu, G.; Zhao, Q.; Tang, W. Chin. J. Org. Chem. 2014, 34, 1919(in Chinese). (徐广庆, 赵庆, 汤文军, 有机化学, 2014, 34, 1919.)
[19] Yang, H.; Sun, J.; Gu, W.; Tang, W. J. Am. Chem. Soc. 2020, 142, 8036.
[20] Lu, Y.; Dong, C.; Huang, J.; Zhou, H.; Wang, W. Future Med. Chem. 2017, 9, 1243.
[21] Fandrick, K. R.; Li, W.; Zhang, Y.; Tang, W.; Gao, J.; Rodriguez, S.; Patel, N. D.; Reeves, D. C.; Wu, J.-P.; Sanyal, S.; Gonnella, N.; Qu, B.; Haddad, N.; Lorenz, J. C.; Sidhu, K.; Wang, J.; Ma, S.; Grinberg, N.; Lee, H.; Tsantrizos, Y.; Poupart, M.-A.; Busacca, C. A.; Yee, N. K.; Lu, B. Z.; Senanayake, C. H. Angew. Chem., Int. Ed. 2015, 54, 7144.
[22] Haddad, N.; Mangunuru, H. P. R.; Fandrick, K. R.; Qu, B.; Sieber, J. D.; Rodriguez, S.; Desrosiers, J. N.; Patel, N. D.; Lee, H.; Kurouski, D.; Grinberg, N.; Yee, N. K.; Song, J. J.; Senanayake, C. H. Adv. Synth. Catal. 2016, 358, 3522.
Options
Outlines

/

〈 〉